271 related articles for article (PubMed ID: 15607843)
1. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
5. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine.
Ponizovsky AM; Grinshpoon A; Margolis A; Cohen R; Rosca P
Addict Behav; 2006 Nov; 31(11):2002-13. PubMed ID: 16524668
[TBL] [Abstract][Full Text] [Related]
6. [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].
Blennow G; Fergusson A; Medvedeo A
Lakartidningen; 2000 Apr; 97(15):1830-3. PubMed ID: 10815411
[TBL] [Abstract][Full Text] [Related]
7. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
De S; Jain R; Ray R; Dhawan A; Varghese ST
Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
[TBL] [Abstract][Full Text] [Related]
8. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
[TBL] [Abstract][Full Text] [Related]
9. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
[TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
14. Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open-label study of five inpatients.
Ang-Lee K; Oreskovich MR; Saxon AJ; Jaffe C; Meredith C; Ellis ML; Malte CA; Knox PC
J Psychoactive Drugs; 2006 Dec; 38(4):505-12. PubMed ID: 17373566
[TBL] [Abstract][Full Text] [Related]
15. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
16. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine for acute heroin detoxification: diffusion of research into practice.
Kovas AE; McFarland BH; McCarty DJ; Boverman JF; Thayer JA
J Subst Abuse Treat; 2007 Mar; 32(2):199-206. PubMed ID: 17306728
[TBL] [Abstract][Full Text] [Related]
18. Development of buprenorphine for the treatment of opioid dependence.
Johnson RE; Fudala PJ
NIDA Res Monogr; 1992; 121():120-41. PubMed ID: 1383825
[TBL] [Abstract][Full Text] [Related]
19. [Experience of using injectable formulation of buprenorphine for the detoxification treatment of heroin dependence patients].
Aso K
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2009 Jun; 44(3):156-66. PubMed ID: 19618840
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
